180 related articles for article (PubMed ID: 34089198)
1. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
2. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
3. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of benign and malignant melanocytic lesions of the conjunctiva using double-staining.
Soon AK; Brownstein S; Tang T; Saleh S; Jiang K; Levac J; Blanco P; Farmer J
Can J Ophthalmol; 2019 Dec; 54(6):699-707. PubMed ID: 31836103
[TBL] [Abstract][Full Text] [Related]
6. Management of pigmented conjunctival lesions.
Oellers P; Karp CL
Ocul Surf; 2012 Oct; 10(4):251-63. PubMed ID: 23084146
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
8. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
9. Differential immunoreactivity of melanocytic lesions of the conjunctiva.
Sharara NA; Alexander RA; Luthert PJ; Hungerford JL; Cree IA
Histopathology; 2001 Oct; 39(4):426-31. PubMed ID: 11683945
[TBL] [Abstract][Full Text] [Related]
10. Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.
Wakefield C; O'Keefe L; Heffron CCBB
Virchows Arch; 2023 Dec; 483(6):847-854. PubMed ID: 37723345
[TBL] [Abstract][Full Text] [Related]
11. In vivo confocal microscopy of pigmented conjunctival tumors.
Messmer EM; Mackert MJ; Zapp DM; Kampik A
Graefes Arch Clin Exp Ophthalmol; 2006 Nov; 244(11):1437-45. PubMed ID: 16598465
[TBL] [Abstract][Full Text] [Related]
12. Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic Lesions.
van Ipenburg JA; de Waard NE; Naus NC; Jager MJ; Paridaens D; Verdijk RM
Invest Ophthalmol Vis Sci; 2019 Jul; 60(8):2950-2957. PubMed ID: 31305861
[TBL] [Abstract][Full Text] [Related]
13. Nucleolar organizer regions in determining malignancy of pigmented conjunctival lesions.
Saornil MA; Marcus DM; Doepner D; Apolone G; Torre V; Albert DM
Am J Ophthalmol; 1993 Jun; 115(6):800-5. PubMed ID: 8506916
[TBL] [Abstract][Full Text] [Related]
14. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.
Lezcano C; Pulitzer M; Moy AP; Hollmann TJ; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Apr; 44(4):503-508. PubMed ID: 31633488
[TBL] [Abstract][Full Text] [Related]
16. Pigmented conjunctival and scleral lesions.
Liesegang TJ
Mayo Clin Proc; 1994 Feb; 69(2):151-61. PubMed ID: 8309267
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of combining PRAME and HMB-45 stains in primary melanocytic tumors.
Rasic D; Korsgaard N; Marcussen N; Precht Jensen EM
Ann Diagn Pathol; 2023 Dec; 67():152211. PubMed ID: 37717457
[TBL] [Abstract][Full Text] [Related]
18. Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
Sugiura M; Colby KA; Mihm MC; Zembowicz A
Am J Surg Pathol; 2007 Feb; 31(2):185-92. PubMed ID: 17255762
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Lezcano C; Jungbluth AA; Busam KJ
Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
[TBL] [Abstract][Full Text] [Related]
20. Conjunctival Primary Acquired Melanosis: Is It Time for a New Terminology?
Jakobiec FA
Am J Ophthalmol; 2016 Feb; 162():3-19.e1. PubMed ID: 26556007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
